Fulcrum Therapeutics Valuation
| FULC Stock | USD 3.15 0.13 4.30% |
At this time, the firm appears to be undervalued. Fulcrum Therapeutics shows a prevailing Real Value of $3.68 per share. The current price of the firm is $3.15. Our model computes the value of Fulcrum Therapeutics from reviewing the firm fundamentals such as Current Valuation of (72.07 M), shares outstanding of 53.98 M, and Profit Margin of (0.12) % as well as analyzing its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Fulcrum Therapeutics' price fluctuation is relatively risky at this time. Calculation of the real value of Fulcrum Therapeutics is based on 3 months time horizon. Increasing Fulcrum Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Fulcrum Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Fulcrum Stock. However, Fulcrum Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.15 | Real 3.68 | Hype 3.16 | Naive 3.42 |
The real value of Fulcrum Stock, also known as its intrinsic value, is the underlying worth of Fulcrum Therapeutics Company, which is reflected in its stock price. It is based on Fulcrum Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Fulcrum Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Fulcrum Therapeutics helps investors to forecast how Fulcrum stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Fulcrum Therapeutics more accurately as focusing exclusively on Fulcrum Therapeutics' fundamentals will not take into account other important factors: Fulcrum Therapeutics Total Value Analysis
Fulcrum Therapeutics is currently expected to have valuation of (72.07 M) with market capitalization of 163.02 M, debt of 17.68 M, and cash on hands of 221.79 M. The negative valuation of Fulcrum Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Fulcrum Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(72.07 M) | 163.02 M | 17.68 M | 221.79 M |
Fulcrum Therapeutics Investor Information
About 97.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.66. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fulcrum Therapeutics recorded a loss per share of 0.16. The entity had not issued any dividends in recent years. Based on the key indicators related to Fulcrum Therapeutics' liquidity, profitability, solvency, and operating efficiency, Fulcrum Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Fulcrum Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Fulcrum Therapeutics has an asset utilization ratio of 30.68 percent. This indicates that the Company is making $0.31 for each dollar of assets. An increasing asset utilization means that Fulcrum Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Fulcrum Therapeutics Ownership Allocation
Fulcrum Therapeutics holds a total of 53.98 Million outstanding shares. The majority of Fulcrum Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Fulcrum Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Fulcrum Therapeutics. Please pay attention to any change in the institutional holdings of Fulcrum Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Fulcrum Therapeutics Profitability Analysis
The company reported the previous year's revenue of 80 M. Net Loss for the year was (9.72 M) with profit before overhead, payroll, taxes, and interest of 16.61 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Fulcrum Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Fulcrum Therapeutics and how it compares across the competition.
About Fulcrum Therapeutics Valuation
The stock valuation mechanism determines Fulcrum Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Fulcrum Therapeutics. We calculate exposure to Fulcrum Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Fulcrum Therapeutics's related companies.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Fulcrum Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 104 people.
Fulcrum Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 53.9 M |
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |